Syncona Limited - Notice of AGM

Syncona

03/07/2024 14:22

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240703:nRSC0299Va&default-theme=true

RNS Number : 0299V  Syncona Limited  03 July 2024

Syncona Limited

Publication of 2024 Annual Report and Notice of Annual General Meeting

3 July 2024

Syncona Ltd, a leading life science investor focused on creating, building and
scaling a portfolio of global leaders in life science, today announces that it
has published its Annual Report and Accounts for the year ended 31 March 2024
("2024 Annual Report") and its Notice of the Annual General Meeting 2024.

In compliance with Listing Rule 9.6.1, these documents will today be filed
with the National Storage Mechanism and will shortly be available for
inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism
(https://data.fca.org.uk/#/nsm/nationalstoragemechanism)

The Notice of the Annual General Meeting 2024 is available on Syncona's
website at
https://www.synconaltd.com/investors/shareholder-information/shareholder-documents/
(https://www.synconaltd.com/investors/shareholder-information/shareholder-documents/)
. The 2024 Annual Report is available on Syncona's website at
https://www.synconaltd.com/investors/results-and-presentations/
(https://www.synconaltd.com/investors/results-and-presentations/) . Printed
copies of these documents are also being posted to shareholders where
requested.

Syncona's Annual General Meeting will be held at 1.00 p.m. on 6 August 2024 at
the offices of Citco Fund Services (Guernsey) Limited, Frances House, Sir
William Place, St. Peter Port, Guernsey, GY1 1GX.

Shareholders are encouraged to ensure that their votes are counted at the 2024
Annual General Meeting by appointing the chair of the 2024 Annual General
Meeting as their proxy in line with the procedures set out in the Notice of
Annual General Meeting.

Enquiries

Syncona Limited

Natalie Garland-Collins / Fergus Witt

Tel: +44 (0) 20 3981 7940

 

FTI Consulting

Ben Atwell / Tim Stamper

Tel: +44 (0) 20 3727 1000

 

About Syncona:

Syncona's purpose is to invest to extend and enhance human life. We do this by
creating, building and scaling companies to deliver transformational
treatments to patients in areas of high unmet need.

 

We aim to build and maintain a diversified portfolio of 20-25 globally leading
life science businesses, across development stage, modality and therapeutic
area, for the benefit of all our stakeholders. We focus on developing
treatments that deliver patient impact by working in close partnership with
world-class academic founders and experienced management teams. Our balance
sheet underpins our strategy, enabling us to take a long-term view as we look
to improve the lives of patients with no or poor treatment options, build
sustainable life science companies and deliver strong risk-adjusted returns to
shareholders.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOAUPUGPMUPCGWW